Tempus AI Raises FY2026 Sales Guidance to $1.595B-$1.605B
Tempus AI (NASDAQ: TEM) has raised its full-year 2026 sales guidance, signaling robust demand for its artificial intelligence-driven healthcare solutions. The company updated its revenue outlook to a range of $1.595 billion to $1.605 billion, an increase from the previous guidance of $1.590 billion to $1.600 billion.
How this was made
The 30-second read
Why it matters
The key tradable update is the guidance revision versus both prior guidance and consensus, alongside the note that FY2026 guidance excludes Personalis acquisition effects. This combination can drive re-pricing of near-term growth expectations while keeping uncertainty elevated into deal timing.
Market read
Guidance upside versus consensus is a direct catalyst, but the after-hours decline signals investors are weighing growth-rate moderation and the exclusion of acquisition impact.
What to watch
FY2026 guidance explicitly excludes the pending Personalis acquisition, so the market may be treating the current outlook as a baseline that could underwhelm until deal closure and integration.
Background
Tempus AI reported Q2 revenue of $382.5M (+22% YoY) and then raised FY2026 sales guidance to $1.595B-$1.605B.
Ticker impact
Tempus AI raised FY2026 sales guidance to $1.595B-$1.605B, lifting the midpoint to $1.600B above the $1.593B consensus estimate.
Near-term volatility likely, with upside bias if investors re-rate growth expectations; downside risk if the market interprets the raise as insufficient versus prior momentum.
The article provides a concrete guidance revision versus prior range and consensus, plus the reported Q2 beat and after-hours decline. It also notes FY2026 guidance excludes Personalis acquisition impact, which can cap near-term upside.
Market effects
Reinforces demand narrative for AI-driven healthcare analytics, potentially supporting sentiment for AI-healthcare peers tied to diagnostics and data licensing.
No specific regional linkage beyond US-listed healthcare/AI growth sentiment.
Limited; story is company-specific with no stated international regulatory or macro catalyst.
Counterpoint
The guidance increase is small relative to the market’s growth expectations, and the stock reaction implies investors may be discounting the raise as not enough to offset concerns about decelerating momentum.
Key entities
- companyTempus AI
Raised FY2026 sales guidance to $1.595B-$1.605B; Q2 revenue beat and after-hours shares declined 2.4%.
- companyPersonalis
Pending acquisition; its impact is excluded from FY2026 guidance and expected to close late 2026 or early 2027.
- personEric Lefkofsky
CEO cited AI investments as drivers of growth in Oncology Diagnostics and Data Licensing.
